Pharmaceutical Patent AnalystVol. 3, No. 5 CommentaryWhat are the risks of second medical use and dosing regimens in pharmaceutical patenting?Christine Kanz & Florian GerhardtChristine KanzAuthor for correspondence: E-mail Address: christine.kanz@rokh-ip.comReimann Osterrieth Köhler Haft, Steinstraße 20, 40212 Düsseldorf, GermanySearch for more papers by this author & Florian GerhardtReimann Osterrieth Köhler Haft, Steinstraße 20, 40212 Düsseldorf, GermanySearch for more papers by this authorPublished Online:6 Nov 2014https://doi.org/10.4155/ppa.14.37AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: advertising materialcustomized formulationdosing regimenscope of protectionsecond medical usespecific purposeReferences1 EPO EBA G 2/08 (Abbott Respiratory).Google Scholar2 Docket number X ZB 5/13, published in GRUR 2014, 461.Google Scholar3 EPO T 0254/93 OJ 98, 285.Google Scholar4 EPO T 0892/94, OJ 00, 1.Google Scholar5 Docket number C-130/11, published in GRURInt 2012, 910.Crossref, Google Scholar6 Docket number 4a O 12/03, published in GRUR-RR 2004, 193 – Ribavirin I.Google Scholar7 Docket number 4a O 145/12 – Ribavirin II.Google Scholar8 Docket number X ZR 236/01, published in GRUR 2007 404 – Carvedilol II.Google ScholarFiguresReferencesRelatedDetailsCited ByRegimes de dosagem em patentes de segundo uso médicoCadernos de Saúde Pública, Vol. 33, No. 9 Vol. 3, No. 5 Follow us on social media for the latest updates Metrics Downloaded 78 times History Published online 6 November 2014 Published in print September 2014 Information© Future Science LtdKeywordsadvertising materialcustomized formulationdosing regimenscope of protectionsecond medical usespecific purposeFinancial & competing interests disclosureThe authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.No writing assistance was utilized in the production of this manuscript.PDF download